Oxford Drug Design achieves in vivo validation for novel cancer treatment

Promising results from mouse study lead to expanded trials

Oxford Drug Design, the Oxford-based AI drug discovery company, has announced further in vivo validation for its first-in-class cancer treatment approach.

The company is developing novel treatments using its pioneering AI platform for oncology and other major diseases with unmet needs.

A recent in vivo mouse colorectal cancer model study showed a 60% life extension, indicating clear efficacy and dose response, while maintaining an acceptable safety profile. These positive results have led to an expanded mouse study, currently showing further progress.

Oxford Drug Design’s advances are enabled by its dual-competence discovery platform. This platform integrates generative AI capabilities with tRNA synthetase expertise, including proprietary structural biology.

The innovative approach targets leucyl-tRNA synthetase, a member of the tRNA synthetase enzyme family. New data demonstrates the potential of the company’s proprietary molecules to modulate tRNA synthetases as a novel cancer treatment.

The lead candidates are part of Oxford Drug Design’s extensive portfolio of new chemical scaffolds. These scaffolds have shown broad activity against the enzyme class.

Dr Paul Finn, CSO of Oxford Drug Design, stated, “Our expertise in generative AI and tRNA-synthetase drug discovery continues to produce breakthrough novel lead series.” He added that their oncology programme’s progress is the latest example of their efficiency and effectiveness.

Dr Alan D. Roth, CEO of Oxford Drug Design, highlighted the significance of their achievement. “This new milestone is a testament to the accuracy and reliability of our computational platform, SynthAI, and our team’s expertise,” he said.

Oxford Drug Design is a pre-clinical therapeutics spinout from Oxford University. The company discovers innovative treatments for cancer and other major diseases using computational methods.